Eyebiotech
Latest round
- Series A
Last raised
- Feb 2022
Total raised
- $31M
Investors
- 4
About Eyebiotech
Based in London, UK, and founded in 2021 by David Guyer and Anthony P. Adamis, Eyebiotech Limited operates as an ophthalmology biotechnology company. As of 2022, David Guyer is the president and CEO of the company., Inc.3 billion. The company develops and delivers a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. The firm provides anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).
Who invested in Eyebiotech
4 investors across 1 round
See all investors in Eyebiotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Feb 3, 2022
Amount
$31M
Investors
Questions about Eyebiotech
Who invested in Eyebiotech?
Eyebiotech has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Eyebiotech raised?
Eyebiotech has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Eyebiotech last raise money?
Eyebiotech's most recent round on record is a Series A, in Feb 2022.
What does Eyebiotech do?
Based in London, UK, and founded in 2021 by David Guyer and Anthony P.
Where is Eyebiotech headquartered?
Eyebiotech is headquartered in London, UK.
Which VCs invest in companies like Eyebiotech?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Eyebiotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Eyebiotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.